This Stock Soared after Successful Treatment of Rare Disease
Soligenix is the top performing stock for Thursday after they announced positive results for the second phase of their drug testing.
Quick overview
- Soligenix (SNGX) experienced a 237% increase in stock price after positive Phase 2 trial results for treating oral ulcers in Behçet's disease.
- The stock surged from $1.25 to $4.16 per share, making it the top performer on the Nasdaq index for Thursday.
- The successful trial of SGX945 (dusquetide) positions Soligenix to potentially dominate the market for treatments of this rare disease.
- Overall, the stock market showed modest gains, with the Nasdaq rising 1.06%, influenced largely by Soligenix's performance.
Soligenix (SNGX) has seen success in their Phase 2 trials for treating oral ulcers, a key symptom of Behçet’s disease, and their stock climbed 237% in Thursday’s trading session.
The top performing stock for Thursday is Soligenix which jumped to $4.16 per share, from $1.25 the previous day. The company announced that their Phase 2a study for proof of concept produced a positive outcome in treating a significant aspect of Behçet’s disease.
The drug trial was designed to treat oral ulcers, which is one of the major symptoms of the disease. With the Phase2a testing turning out well, the company is poised to corner the market for treatment of the rare disease. The chronic inflammatory condition is most common in Asia and the Middle East.
Soligenix has been testing a new drug SGX945 (dusquetide), and if successful, the drug could significantly improve the quality of life for those affected by the disease. Skin lesions, inflammation of the eyes, and oral sores are all common symptoms of the disease.
Soligenix Tops the Stock Market
The Nasdaq Composite rose 1.06% in Thursday’s afternoon trading, and Soligenix topped the Nasdaq index. No other stock even came close to SNGX’s change compared to the previous day, and that one stock almost single handedly drove the Nasdaq higher than its counterpart indices. We will likely see this stock retreat over the next couple days as it settles from its sky-high gains.
Thursday was mostly calm for the stock market, with the Dow Jones up 0.10% and the S&P 500 up 0.51% as investors waited for an answer from federal courts on the tariff question as well as from China and the United States to determine what rate their tariffs will settle at. The stock market is also dealing with Wednesday’s decision from the Federal Reserve to hold off on interest rate cuts for now.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
Save